Buparlisib
Transformed Recurrent Non-Hodgkin Lymphoma
Mayo ClinicSmall moleculeEarly Phase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
411 Active assets in the Transformed Recurrent Non-Hodgkin Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
CYCLOSPORIN A Memorial Sloan Kettering Cancer Center | Phase 3 | BBB |
PEGASPARGASE Ciusss de L'Est de l'Île de Montréal | Phase 4 | BBB |
Inno-206 National Cancer Institute (NCI) | Phase 4 | BBB |
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE Mwanasha Merrill, MD | Phase 3 | BBB |
Entecavir Fudan University | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Buparlisib is also rated in:
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular LymphomaDormant
CCC
Indicative ·
54 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →